July 23, 2026 -
The Royal Orthopaedic Hospital NHS Foundation Trust researchers publish the first clinical evidence supporting the use of real-time fluorescence imaging during revision knee arthroplasty for periprosthetic joint infection.
PITTSBURGH, USA and BIRMINGHAM, UK, July 23, 2026 – MolecuLight and The Royal Orthopaedic Hospital NHS Foundation Trust
… Read MoreJuly 8, 2026 -
New integration streamlines wound documentation by bringing bacterial fluorescence imaging, digital wound measurements, and thermal imaging directly into ModMed EHR workflows.
Pittsburgh, USA – July 8, 2026 – MolecuLight, a global leader in point-of-care wound imaging, today announced that the MolecuLightDX® is now available through the ModMed
… Read MoreFebruary 19, 2026 -
MolecuLight Victorious in its Efforts to Prove Adiuvo Diagnostics Private Ltd. Did Not Merit a Patent
Pittsburgh, USA – February 19, 2026 – MolecuLight® Corp., the global leader in real-time detection of elevated bacterial loads in wounds through point-of-care fluorescence imaging, is pleased to announce that India’s
… Read MoreFebruary 5, 2026 -
Pittsburgh, USA, February 05, 2026 – MolecuLight today announced that the United States International Trade Commission (“ITC”) has formally instituted an investigation into the SnapshotGLO product, following the complaint previously filed by MolecuLight Corp and MolecuLight Inc. The investigation will examine whether the SnapshotGLO product infringes U.S.
… Read MoreJanuary 29, 2026 -
Pittsburgh, USA, January 29, 2026 – MolecuLight today announced that its MolecuLightDX® wound measurement has been qualified by the U.S. Food and Drug Administration (FDA) as a Medical Device Development Tool (MDDT). The FDA’s MDDT program qualifies select, scientifically validated tools for use in medical device development
… Read MoreJanuary 13, 2026 -
Pittsburgh, PA, USA – January 13, 2026 – MolecuLight Corp. and MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria and digital wound measurement, today announced that it has filed a complaint with the United States International Trade Commission (ITC) requesting
… Read MoreDecember 16, 2025 -
Tissue Analytics moves toward a unified, AI-powered imaging experience that seamlessly connects data from point-of-care devices to EHR workflows
PITTSBURGH, PA – Dec. 16, 2025 – Net Health today announced the platform integration of MolecuLight with Tissue Analytics, its AI-powered mobile wound imaging and analytics solution. This enables
… Read MoreDecember 9, 2025 -
Streamlined integration enhances wound care by combining bacterial detection, digital wound measurements, and thermal imaging with direct Oracle Health Foundation EHR connectivity
Pittsburgh, USA, December 9, 2025 – MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment and an Oracle partner, today announced the
… Read MoreNovember 13, 2025 -
Pittsburgh, USA – November 13, 2025 – MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment, is proud to announce the publication of a landmark international consensus report, developed by leading experts in wound care and surgery from across the United States. The report,
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s
Technology
Breakthrough Designation
MolecuLight
i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2026
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.